Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Return on Assets (2020 - 2025)

Historic Return on Assets for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 0.33%.

  • Evoke Pharma's Return on Assets rose 1400.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.44% for FY2024, which is 3900.0% up from last year.
  • Evoke Pharma's Return on Assets amounted to 0.33% in Q3 2025, which was up 1400.0% from 0.33% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Return on Assets registered a high of 0.3% during Q1 2025, and its lowest value of 1.04% during Q4 2023.
  • Over the past 5 years, Evoke Pharma's median Return on Assets value was 0.65% (recorded in 2022), while the average stood at 0.64%.
  • In the last 5 years, Evoke Pharma's Return on Assets tumbled by -3900bps in 2023 and then skyrocketed by 7100bps in 2024.
  • Over the past 5 years, Evoke Pharma's Return on Assets (Quarter) stood at 0.78% in 2021, then increased by 16bps to 0.65% in 2022, then plummeted by -60bps to 1.04% in 2023, then soared by 68bps to 0.34% in 2024, then grew by 2bps to 0.33% in 2025.
  • Its last three reported values are 0.33% in Q3 2025, 0.33% for Q2 2025, and 0.3% during Q1 2025.